Presentations & Articles

Note: Some of the documents linked to this page are in Portable Document Format (PDF), and require the Adobe® Acrobat Reader for viewing. If you do not have the Acrobat Reader, visit to download.

A Guide to Time Lag and Time Lag Shortening Strategies in Oncology-Based Drug Development
Berna Uygur, Josh Duberman, and Steven M. Ferguson
J Commer Biotechnol. 2017 May;23(2):75-81.
Image:PDF logo
Beyond Hybrid Licenses—Strategies for Post Patent Expiration Payments in the United States
Patrick Gattari, Steven Ferguson, David Crichton, and Bryan Helwig
les Nouvelles. 2017 Mar;52(1):31-6.
Image:PDF logo
Licensing the Technology: Biotechnology Commercialization Strategies Using University and Federal Labs
Steven M. Ferguson and Uma S. Kaundinya
In: Craig Shimasaki, ed. Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies. (Elsevier Inc.) 2014:185-206.
Image:PDF logo
NIH Inventions Translate into Drugs and Biologics with High Public Health Impact
Sabarni K. Chatterjee and Mark L. Rohrbaugh
Nat Biotechnol. 2014 Jan 9;32(1):52-8.
If The Sky Were The Limit, What Would You Do In Technology Transfer?
Gary Keller, Fizie Haleem, Steven Ferguson, Al Jordan, and Cheryl Cejka
les Nouvelles. 2013 Mar;47(1):66-70.
Image:PDF logo
Partnering with the NIH: Now part of the "Value Proposition" for start-ups
Steven M. Ferguson
J Commer Biotechnol. 2012 Apr 1;18(2):60-67.
Image:PDF logo
License Compliance Issues for Biopharmaceuticals: Special Challenges for Negotiations between Companies and Non-Profit Research Institutions
Todd A. Ponzio, Hans Feindt, and Steven M. Ferguson
les Nouvelles, 2011 Sep;46(3):216-25.
Image:PubMedCentral logo
The Role of Public-Sector Research in the Discovery of Drugs and Vaccines
Ashley J. Stevens, Jonathan J. Jensen, Katrine Wyller, Patrick C. Kilgore, Sabarni Chatterjee, and Mark L. Rohrbaugh
N Engl J Med. 2011 Feb 10;364(6):535-41.


Presentations & Articles Archive